Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Baden-Baden – page 41

1 153 clinical trials in Baden-Baden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Baden-Baden at a glance
1 153
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 153 trials in Baden-Baden

Open in trial search

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Efficacy and Safety of REGN7508, REGN9933, and Rivaroxaban in Adults with Peripheral Artery Disease after Recent Lower‑Extremity Revascularization

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Hypercholesterolaemia

Not yet recruiting

Effect of laroprovstat/rosuvastatin combination versus laroprovstat, rosuvastatin, and placebo on LDL‑C in hypercholesterolemia patients not previously treated with lipid‑lowering therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus+2

Not yet recruiting

Efficacy and Safety of Olatorepatide in Adults with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olatorepatide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Baden-Baden

What the registry says about research in the country

01 Eye Diseases and Ocular Physiology

Clinical research in Baden-Baden includes studies focused on eye diseases and ocular physiological phenomena, with attention on atrophic age-related macular degeneration. These trials are exploring ways to slow disease progression and better understand vision-related decline.

  • Testing a new approach for geographic atrophy linked to AMD
  • Evaluating treatment effectiveness in progressive retinal disease

The goal is to improve care for patients facing gradual loss of vision through more effective targeted therapies.

02 Neoplasms in Breast Cancer Research

A major part of the clinical trial activity in the city centers on breast cancer, including HER2+, HR+/HER2-, and triple-negative early breast cancer. These studies are examining new treatment combinations to strengthen disease control and improve long-term outcomes.

  • Assessing new therapy combinations for HER2+ early breast cancer
  • Comparing treatment strategies in HR+/HER2- early breast cancer
  • Studying options for triple-negative early breast cancer

Research in this area is aimed at improving response rates and reducing the chance of recurrence after initial treatment.

03 Hemic and Lymphatic Diseases

Trials in hematologic malignancies are investigating new strategies for patients with high-risk chronic lymphocytic leukemia. The focus is on whether newer drug combinations can offer stronger disease control than current standard approaches.

  • Evaluating combination treatment for high-risk CLL
  • Studying outcomes in patients with adverse genetic risk factors

These studies are designed to improve progression control and support more personalized treatment choices.

04 Ovarian and Gynecologic Cancer

Another active research area involves advanced ovarian cancer and related gynecologic cancers, including fallopian tube cancer, primary peritoneal cancer, and clear cell carcinoma of the ovary. The trials are examining treatment strategies for patients with no visible residual tumor after surgery.

  • Studying maintenance approaches in HRD-positive high-grade ovarian cancer
  • Evaluating recurrence prevention after primary tumor debulking

These efforts aim to extend recurrence-free survival and refine post-surgical treatment planning.

05 Personalized Oncology in Early Breast Cancer

Several studies are exploring personalized cancer therapy for early-stage breast cancer, using treatment selection to match individual risk profiles. This includes approaches that combine targeted medicine, endocrine therapy, and other systemic treatments.

  • Testing personalized treatment for intermediate- to high-risk HR+/HER2- breast cancer
  • Comparing targeted therapy with standard adjuvant care
  • Improving invasive disease-free survival in early cancer care

In Baden-Baden, this line of research reflects a broader move toward more tailored and effective cancer treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.